Increased expression and accumulation of GDF15 in IPF extracellular matrix contribute to fibrosis.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
22 08 2022
Historique:
received: 09 07 2021
accepted: 15 07 2022
entrez: 22 8 2022
pubmed: 23 8 2022
medline: 24 8 2022
Statut: epublish

Résumé

Idiopathic pulmonary fibrosis (IPF) is a chronic disease of unmet medical need. It is characterized by formation of scar tissue leading to a progressive and irreversible decline in lung function. IPF is associated with repeated injury, which may alter the composition of the extracellular matrix (ECM). Here, we demonstrate that IPF patient-derived pulmonary ECM drives profibrotic response in normal human lung fibroblasts (NHLF) in a 3D spheroid assay. Next, we reveal distinct alterations in composition of the diseased ECM, identifying potentially novel associations with IPF. Growth differentiation factor 15 (GDF15) was identified among the most significantly upregulated proteins in the IPF lung-derived ECM. In vivo, GDF15 neutralization in a bleomycin-induced lung fibrosis model led to significantly less fibrosis. In vitro, recombinant GDF15 (rGDF15) stimulated α smooth muscle actin (αSMA) expression in NHLF, and this was mediated by the activin receptor-like kinase 5 (ALK5) receptor. Furthermore, in the presence of rGDF15, the migration of NHLF in collagen gel was reduced. In addition, we observed a cell type-dependent effect of GDF15 on the expression of cell senescence markers. Our data suggest that GDF15 mediates lung fibrosis through fibroblast activation and differentiation, implicating a potential direct role of this matrix-associated cytokine in promoting aberrant cell responses in disease.

Identifiants

pubmed: 35993367
pii: 153058
doi: 10.1172/jci.insight.153058
pmc: PMC9462497
doi:
pii:

Substances chimiques

GDF15 protein, human 0
Growth Differentiation Factor 15 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NHLBI NIH HHS
ID : P01 HL108793
Pays : United States

Références

J Clin Invest. 2014 Apr;124(4):1622-35
pubmed: 24590289
Eur Respir J. 2017 Feb 23;49(2):
pubmed: 28232409
Inflammation. 2017 Dec;40(6):2062-2073
pubmed: 28785877
Cold Spring Harb Perspect Biol. 2011 Nov 01;3(11):a005017
pubmed: 21900405
Am J Respir Cell Mol Biol. 2016 Sep;55(3):429-38
pubmed: 27093475
Int J Mol Sci. 2018 Nov 15;19(11):
pubmed: 30445777
Am J Respir Cell Mol Biol. 2006 Aug;35(2):175-81
pubmed: 16543609
Exp Cell Res. 1986 Feb;162(2):423-35
pubmed: 3510880
Ann Am Thorac Soc. 2015 Mar;12 Suppl 1:S24-9
pubmed: 25830830
Am J Physiol Lung Cell Mol Physiol. 2019 Oct 1;317(4):L510-L521
pubmed: 31432710
Front Med (Lausanne). 2020 Dec 03;7:594137
pubmed: 33344478
Front Immunol. 2020 May 19;11:951
pubmed: 32508832
Cell Metab. 2018 Sep 4;28(3):353-368
pubmed: 30184485
J Exp Med. 2011 Feb 14;208(2):217-25
pubmed: 21242297
Oncotarget. 2016 Jan 5;7(1):860-72
pubmed: 26497212
Biomed Pharmacother. 2019 Oct;118:109230
pubmed: 31351434
Am J Respir Crit Care Med. 2001 Oct 1;164(7):1171-81
pubmed: 11673205
Int J Biochem Cell Biol. 2008;40(10):2174-82
pubmed: 18395486
J Pathol. 2016 Dec;240(4):397-409
pubmed: 27623753
Am J Respir Crit Care Med. 2005 Apr 15;171(8):889-98
pubmed: 15563636
Eur Respir J. 2013 Dec;42(6):1633-45
pubmed: 23520313
Invest Ophthalmol Vis Sci. 2000 Mar;41(3):756-63
pubmed: 10711691
Oncotarget. 2016 Mar 1;7(9):9634-44
pubmed: 26909594
FASEB J. 2014 Dec;28(12):5299-310
pubmed: 25252739
Int J Mol Sci. 2021 Oct 15;22(20):
pubmed: 34681812
Clin Cancer Res. 2010 Aug 1;16(15):3851-9
pubmed: 20534737
Int J Obes (Lond). 2018 Mar;42(3):561-571
pubmed: 29026214
Clin Chem. 2017 Jan;63(1):140-151
pubmed: 28062617
Cell. 2019 Aug 22;178(5):1231-1244.e11
pubmed: 31402172
Circ Res. 2006 Feb 17;98(3):342-50
pubmed: 16397142
Nat Med. 2011 May;17(5):581-8
pubmed: 21516086
Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6482-6495
pubmed: 27918822
PLoS Biol. 2020 Jan 16;18(1):e3000599
pubmed: 31945054
Fibrogenesis Tissue Repair. 2011 Oct 19;4(1):23
pubmed: 22011363
Phytomedicine. 2020 Nov;78:153298
pubmed: 32781391
Aging Cell. 2019 Dec;18(6):e13013
pubmed: 31389184
PLoS One. 2017 Nov 21;12(11):e0187349
pubmed: 29161287
Nat Med. 2017 Oct;23(10):1215-1219
pubmed: 28846098
Am J Respir Crit Care Med. 1997 Dec;156(6):1937-44
pubmed: 9412578
Am J Respir Cell Mol Biol. 2014 May;50(5):848-52
pubmed: 24605795
J Cell Sci. 1992 Jul;102 ( Pt 3):447-56
pubmed: 1506427
Oncotarget. 2016 Feb 16;7(7):7732-46
pubmed: 26741507
PLoS Biol. 2008 Dec 2;6(12):2853-68
pubmed: 19053174
Am J Physiol Lung Cell Mol Physiol. 2012 Aug 1;303(3):L169-80
pubmed: 22659883
PLoS One. 2019 May 10;14(5):e0216602
pubmed: 31075112
Am J Pathol. 2016 May;186(5):1066-77
pubmed: 27021937
J Invest Dermatol. 2009 Feb;129(2):383-91
pubmed: 18754039
N Engl J Med. 2018 May 10;378(19):1811-1823
pubmed: 29742380
Oncotarget. 2017 Oct 10;8(55):94393-94406
pubmed: 29212236
Gene. 1999 Sep 3;237(1):105-11
pubmed: 10524241
Am J Respir Crit Care Med. 2012 Nov 1;186(9):866-76
pubmed: 22936357
Proc Am Thorac Soc. 2012 Jul;9(3):111-6
pubmed: 22802283
Anal Biochem. 1994 Feb 1;216(2):276-84
pubmed: 8179182
Lancet. 2011 Dec 3;378(9807):1949-61
pubmed: 21719092
J Clin Invest. 2018 Jan 2;128(1):74-84
pubmed: 29293092
Eur Respir J. 2017 Mar 15;49(3):
pubmed: 28298399
Nat Commun. 2017 Feb 23;8:14532
pubmed: 28230051
PLoS One. 2018 Mar 16;13(3):e0193057
pubmed: 29547661
Cell Biosci. 2019 Dec 9;9:98
pubmed: 31827764
Nature. 2017 Oct 12;550(7675):255-259
pubmed: 28953886
BMC Bioinformatics. 2011 Jul 28;12:307
pubmed: 21798031
Development. 2019 Oct 1;146(20):
pubmed: 31575608
Front Bioeng Biotechnol. 2020 Dec 22;8:609653
pubmed: 33425874
J Pharmacol Exp Ther. 1987 Dec;243(3):1185-94
pubmed: 2447265
Am J Respir Crit Care Med. 2021 May 1;203(9):1149-1157
pubmed: 33080140
Matrix Biol. 2018 Nov;73:64-76
pubmed: 29274939
J Exp Med. 2020 Feb 13;217(3):e20190103
pubmed: 32997468
FEBS Open Bio. 2020 Dec;10(12):2750-2760
pubmed: 33098235
Pharmacol Ther. 2019 Jun;198:46-58
pubmed: 30790643
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11514-9
pubmed: 9326641
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Arthritis Rheumatol. 2014 Feb;66(2):418-27
pubmed: 24504814
Blood. 2016 Jul 28;128(4):529-41
pubmed: 27235139
Gene. 1997 Dec 5;203(1):17-26
pubmed: 9426002
Sci Transl Med. 2017 Oct 18;9(412):
pubmed: 29046435
Nat Med. 2017 Oct;23(10):1150-1157
pubmed: 28846097
Nat Med. 2017 Oct;23(10):1158-1166
pubmed: 28846099
Nat Med. 2007 Nov;13(11):1333-40
pubmed: 17982462
JCI Insight. 2020 Jun 18;5(12):
pubmed: 32554926
Am J Respir Crit Care Med. 2019 Jun 15;199(12):1517-1536
pubmed: 30554520
Cytokine. 1998 Apr;10(4):281-9
pubmed: 9617573
Am J Respir Cell Mol Biol. 2016 May;54(5):647-55
pubmed: 26796672
Trends Mol Med. 2016 Apr;22(4):303-316
pubmed: 26979628
J Clin Invest. 2018 Jan 2;128(1):45-53
pubmed: 29293088
Exp Cell Res. 2020 Jun 15;391(2):112010
pubmed: 32305327

Auteurs

Agata Radwanska (A)

Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Christopher Travis Cottage (CT)

Bioscience COPD/IPF, Research and Early Development, R&I, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.

Antonio Piras (A)

Bioscience In Vivo, Research and Early Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Catherine Overed-Sayer (C)

Bioscience COPD/IPF, Research and Early Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.

Carina Sihlbom (C)

Proteomics Core Facility of Sahlgrenska Academy, University of Gothenburg, Sweden.

Ramachandramouli Budida (R)

Translational Science and Experimental Medicine, Research and Early Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Catherine Wrench (C)

Bioscience COPD/IPF, Research and Early Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.

Jane Connor (J)

Bioscience COPD/IPF, Research and Early Development, R&I, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.

Susan Monkley (S)

Translational Science and Experimental Medicine, Research and Early Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Petra Hazon (P)

Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Holger Schluter (H)

Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Matthew J Thomas (MJ)

Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Cory M Hogaboam (CM)

Cedar-Sinai, Los Angeles, California, USA.

Lynne A Murray (LA)

Bioscience COPD/IPF, Research and Early Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH